Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biohaven (BHVN) EBITDA (2021 - 2026)

Biohaven has reported EBITDA over the past 6 years, most recently at -$130.6 million for Q1 2026.

  • Quarterly results put EBITDA at -$130.6 million for Q1 2026, up 41.1% from a year ago — trailing twelve months through Mar 2026 was -$644.9 million (up 27.65% YoY), and the annual figure for FY2025 was -$745.4 million, up 15.79%.
  • EBITDA reached -$130.6 million in Q1 2026 per BHVN's latest filing, up from -$142.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$68.9 million in Q3 2022 and bottomed at -$319.7 million in Q2 2024.
  • Median EBITDA over the past 5 years was -$160.1 million (2024), compared with a mean of -$159.8 million.
  • The largest annual shift saw EBITDA tumbled 319.42% in 2022 before it skyrocketed 55.49% in 2023.
  • Over 5 years, EBITDA stood at -$213.4 million in 2022, then grew by 27.97% to -$153.7 million in 2023, then dropped by 23.56% to -$189.9 million in 2024, then rose by 24.85% to -$142.7 million in 2025, then increased by 8.52% to -$130.6 million in 2026.
  • Business Quant data shows EBITDA for BHVN at -$130.6 million in Q1 2026, -$142.7 million in Q4 2025, and -$173.4 million in Q3 2025.